VERA Vera Therapeutics, Inc.

Nasdaq veratx.com


$ 30.29 $ -0.19 (-0.62 %)    

Tuesday, 14-Oct-2025 19:49:17 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 30.3
$ 30.09
$ 27.35 x 30
$ 32.75 x 50
$ 29.58 - $ 30.83
$ 18.53 - $ 51.61
1,024,037
na
1.93B
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-28-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-25-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 06-24-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 6-stocks-goldman-sachs-says-are-poised-for-potential-acquisition-in-next-12-months--including-a-huge-200-winner

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

 jp-morgan-maintains-overweight-on-vera-therapeutics-lowers-price-target-to-53

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and lowers the price target from $...

 vera-therapeutics-files-for-offering-of-up-to-200m-class-a-common-stock

- SEC Filing

 vera-therapeutics-q2-2025-eps-120-misses-083-estimate-vera-reported-5568m-in-cash-cash-equivalents-and-marketable-securities

Vera expects cash position to be sufficient to fund operations through potential approval and us commercial launch of Atacicept...

 wolfe-research-downgrades-vera-therapeutics-to-peer-perform

Wolfe Research analyst Andy Chen downgrades Vera Therapeutics (NASDAQ:VERA) from Outperform to Peer Perform.

 vera-therapeutics-secures-500m-credit-facility-with-lower-rates-boosting-financial-flexibility

Vera Therapeutics, Inc. ("Vera"), a late clinical-stage biotechnology company focused on developing and commercializing...

 scotiabank-maintains-sector-outperform-on-vera-therapeutics-raises-price-target-to-65

Scotiabank analyst Greg Harrison maintains Vera Therapeutics (NASDAQ:VERA) with a Sector Outperform and raises the price tar...

 kidney-health-focused-vera-therapeutics-stock-price-spikes-on-heels-of-successful-trial-data

Vera Therapeutics' share price surged over 65% during the pre-market trading session after the company released ORIGIN Phas...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION